Education and Training
Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo to match tofacitinib
- drug: Tofacitinib 10 MG [Xeljanz]
Eligibility
Inclusion Criteria:
- Patients undergoing esophagectomy
Exclusion Criteria:
- Patients with more than mild pulmonary dysfunction
- Patients with any neuromuscular disease that might compromise diaphragm function
- Patients with abnormal liver or kidney function
- Patients taking any immunosuppressant medication (including prednisone) or antifungal
medications
- History of tuberculosis
- Weight loss of >5% of body weight over previous 6 months
- Pregnancy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Study Team
650-721-6561
I'm interested